Paper Details

  1. Home
  2. Paper Details

Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial.

Author: , BlåfieldHarri, HannonenPekka, JärvenpääSalme, KarjalainenAnna, KautiainenHannu, KorpelaMarkku, LaasonenLeena, Leirisalo-RepoMarjatta, MöttönenTimo, PuolakkaKari, RantalaihoVappu

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Early and intensive treatment for rheumatoid arthritis (RA) has been shown to slow joint damage for up to 5 years. This study examines the progression of joint damage beyond that time in people with early RA who initially received either a combination of three disease-modifying antirheumatic drugs (DMARDs) or a single DMARD.
Paper Details　
Original Abstract of the Article :
Early treatment of rheumatoid arthritis (RA) has been shown to retard the development of joint damage for a period of up to 5 years. The aim of this study was to evaluate the radiologic progression beyond that time in patients with early RA initially treated with a combination of three disease-modif...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2911916/

データ提供：米国国立医学図書館（NLM）

Early Combination Therapy for Rheumatoid Arthritis

Rheumatoid arthritis (RA), like a persistent sandstorm in the desert, can cause pain, inflammation, and joint damage. This study examines the long-term effects of early treatment with a combination of disease-modifying antirheumatic drugs (DMARDs) compared to treatment with a single DMARD. Researchers followed patients for 11 years to evaluate the impact of these treatment strategies on radiologic progression of RA.

Early Combination Therapy Shows Long-Term Benefits

The study found that patients who received early combination DMARD therapy exhibited significantly slower radiologic progression of RA over an 11-year period compared to those treated with a single DMARD. This suggests that early and aggressive treatment can have lasting benefits in managing RA and minimizing its damaging effects. It's like planting a seed of hope in the desert, nurturing its growth to create a sustainable and thriving oasis.

Importance of Early Intervention for RA

The results of this study highlight the importance of early intervention in RA. Early and aggressive treatment can significantly impact the long-term course of the disease, minimizing pain, inflammation, and joint damage. This is like providing timely irrigation to a desert garden, ensuring its growth and resilience. Early diagnosis and treatment are crucial to managing RA effectively.

Dr. Camel's Conclusion

This study provides compelling evidence for the benefits of early combination therapy for rheumatoid arthritis. Early intervention can significantly impact the long-term course of the disease, like providing a lifeline in a harsh desert. By understanding the importance of early and aggressive treatment, we can help patients navigate the challenges of RA with greater hope and improved quality of life.

Date :
  1. Date Completed 2010-11-24
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

20576092

DOI: Digital Object Identifier

PMC2911916

Related Literature

Article Analysis
・Effective treatment of rheumatoid arthritis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.